- Home
- OVID vs ANTX Comparison
OVID vs ANTX Comparison
Compare OVID & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OVID | ANTX |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 117.5M | 135.4M |
| IPO Year | 2017 | 2022 |
Fundamental Metrics
Financial Performance| Metric | OVID | ANTX |
|---|---|---|
| Price | $2.51 | $3.81 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $4.20 | $2.00 |
| AVG Volume (30 Days) | 3.1M | ★ 3.5M |
| Earning Date | 03-18-2026 | 03-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 3.90 | ★ 32.56 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $7,252,000.00 | N/A |
| Revenue This Year | $1,077.56 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1181.27 | N/A |
| 52 Week Low | $0.24 | $1.00 |
| 52 Week High | $2.72 | $6.91 |
Technical Indicators
Market Signals| Indicator | OVID | ANTX |
|---|---|---|
| Relative Strength Index (RSI) | 76.72 | 58.66 |
| Support Level | $1.31 | $1.05 |
| Resistance Level | N/A | $6.91 |
| Average True Range (ATR) | 0.21 | 0.91 |
| MACD | 0.07 | -0.04 |
| Stochastic Oscillator | 82.11 | 47.05 |
Price Performance
Historical ComparisonAbout OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.